*** VIVK is Lookin to Rebound to Higher Highs ***

11/16/2009 1:49 PM

Penny Stocks by: Free Hot Penny Stocks

Buy VIVK Online for $0. Trade stocks for free on Zecco.com.

VIVK is starring in our face and SCREAMING VALUE!!! VIVK has hit a high in the .60`s and has pulled back in the mid .50`s for a nice reload!!! VIVK is on the uptrend for the week and we are looking for higher HIGHS, potentially profit in the .75 to .80 area!!!! VIVK trading that high would mean a Potential 50% Gain from this level!!! STAY TUNED FOR OUR NEXT PICK TONIGHT. VIVK is a KEEPER THIS WEEK! *** VIVK.OB***

Our Latest Pick - VIVK - is using its diversity to Make a Grab at a $ 1.9 Billion Marketplace!!! VIVK is worth the research, attention and investment right now!!! Conduct your own research starting with the basic information below. This company is The Real Deal!!! About Vivakor, Inc.

Vivakor, Inc. is a transdisciplinary research company that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds. Vivakor also provides contract research services for third parties.

Vivakor`s business model is to be a research hub focused on areas that have both an identified scientific need and a substantial market opportunity with a significant market. This approach is intended to provide the necessary environment of transdisciplinary collaboration and cross-pollination to advance research and technology acquisition. Vivakor`s mission is to advance or acquire distinct intellectual property and technologies that improve the quality of life for individual patients, researchers, clinicians and consumers. Vivakor believes that the development and commercialization of substantive technologies and cures for complex human conditions, illnesses and diseases require a sophisticated approach with contribution from many areas of business and scientific expertise. Vivakor`s research and the technology it acquires are anchored by its relationship with collaborative partners and product-specific commercialization strategies. From the commencement of product conception or acquisition, through development and commercialization, the Company expects to have collaborative partners or licensing arrangements in place for each of its products. Vivakor expects this model to provide several advantages, including: (i) a more efficient research and development process; (ii) a quicker time to market after completion of development; and (iii) the value-add growth to the hub company, Vivakor, through commercialization and subsidiary spin-off.

Vivakor has commenced developing numerous products and currently has one pending utility patent. In October, 2008, it acquired a patented MRI software technology that it intends to develop. Vivakor generally intends to commercialize its products, after completion of development and any required regulatory approvals, primarily through one of three methods: (i) a sale of the technology; (ii) licensing of the product to a manufacturer or distributor or; (iii) by directly manufacturing, marketing and selling the products.

Product Research Divisions Vivakor`s research efforts are divided into four primary areas of medical and biotechnological development. These are:

1. Molecular Medicine. The goal of this division centers on the development of biologically relevant molecules, tests and methods and their application in the practice of medicine.

Vivakor plans to translate systems biology (genomics, proteomics, metabalomics, etc.) insights of the molecular and cellular basis of disease into commercializable theranostic (diagnostic/therapeutic) products.

Vivakor scientists will be participants in the discovery and development of new drugs and the early diagnosis of disease states.

The central aim of the molecular medicine division is cancer detection and wound healing, which we anticipate will lead to the development of customized treatments. Research in stem cell biology and nuclear reprogramming is a critical element in this research.

2. Electro-Optics. This division is charged with the development of biomedical and related consumer products that incorporate optical and electronic engineering. Vivakor has actively designed, built and tested several new electro-optic devices to reach previously un-served or underserved areas of the biomedical device market and believes the market potential during the first 12 months of commercialization of these products is over $15 million. Products scheduled for development in this area include:

- VivaSight: a digital photorefractor that is intended to modernize child vision screening. Approval has been granted from Western Institutional Review Board (20080731) to conduct human validation studies of the VivaSight technology on children. This study is currently being conducted at The University of Iowa Hospitals and Clinics.

- Clinical Biomolecular Sensor (CBS): a label free multiplexed approach for use in the detection and diagnosis of complex human conditions (cancer, infectious diseases, cardiovascular disease, metabolic disorders, auto immune and inflammatory diseases)Multi-spectral Imaging: devices to examine burn degree and cutaneous melanoma and - Spectroscopic devices: to track wound healing and ear infection. With the acquisition of HealthAmerica`s SLICES(TM) technology, the Company plans to adapt and upgrade this technology to produce enhanced MRI images, which are expected to improve MRI resolution while providing additional data such as blood flow velocity in imaged tissues. The Company believes its potential market share for this product is over $300 million annually .

3. Biological Handling. Vivakor has developed commercial products for cryogengenic preservation, and storage through its VivaThermic Cryovials (USPTO Utility Patent # 12423998) which are currently being sold and have improved temperature control and were designed to improve cryopreservation and thawing of sensitive biological material. Vivakor expects that the market potential for its products is over $10 million over the next 12 months. It plans to continue to explore new techniques to improve methods and products employed for cryogenic preservation, storage and handling.

Future research plans for this division include:

- stem cell specific improved cryovials; - cryogenic devices for temperature maintenance and sample transport); - a cryogenic biopsy device (Cryopsy); and - improved modular cryogenic freezer designs. 4. Natural and Formulary Products. This division plans to focus on the investigation, validation and adaptation of medical herbalism or botanical medicine. The Company has already developed a series of nutraceutical formulations, including VivaBlend, and plan to develop additional nutraceuticals, botanicals and supplements. Vivakor recently received a 25,000 unit purchase order for one of our products from Regeneca, International. Future products for this division include:

- fruit and vegetable extract for the protection of digestive system - fresh fruit and vegetable extract for antioxidant supplements; and - jam and jelly formula to contain both antioxidant supplements as well as bone & cartilage supplements for healthy joints More information can be found about Vivakor at www.vivakor.com.

About Regeneca International, Inc.

Regeneca(TM) International, Inc. was formed to create and commercialize products that help consumers improve their health, battle the signs and symptoms of aging and to assist you "regenerate their life" through its family of natural, organic and phytochemical infused products. The corporate creed is to regenerate the human genetic environment through ecology centric science. All REGENECA(TM) products must fit the highest standard of conservation, and reduced carbon footprint. The products must also work to preserve and promote the user`s health at the most elemental level of life; the genetic level. The Company`s products and philosophy are designed to reconnect the consumer to the Earth`s source of healing properties, but with a symbiotic approach. This is the Company`s "Whole Earth, Whole Body Approach to Health." Already a market presence in the multibillion dollar nutraceutical market, Regeneca`s proprietary, direct to consumer; marketing strategy has pushed the company to the forefront of emerging consumer product companies.

Regeneca anticipates at least a 500% increase in sales in 2010 and a similar increase in 2011.

More information can be found about Regeneca International, Inc. at www.regeneca.com .

Vivakor is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, which extend or improve life.

VIVK information can be found at www.vivakor.com.

VIVK has seen a tremendous upswing in terms of volume this past week and our analysts have only good things to say about Vivakors future.

VIVK produced gains of about 20% in the past few days with plenty more potential in the upcoming weeks!!! Vivakor Inc. has released exciting news that should have our Members keyed up on this new alert!!! Wednesday Nov. 11, 2009 - Vivakor Announces Distribution & Purchase Order Contract with Regeneca International, Inc. For Cutting-Edge Nutraceutical Formulation The Company today announced it has completed an exclusive distribution agreement with consumer product specialist, Regeneca International, Inc.

( www.regeneca.com) for one of its proprietary, cutting-edge nutraceutical formulations. In conjunction with this agreement was an immediate purchase order from Regeneca for 25,000 units of the product. Both companies hope this agreement initiates a long term relationship for product commercialization. This purchase also represents to another substantial revenue stream for Vivakors emerging nutraceutical division. Vivakor CEO Tannin Fuja expressed his enthusiasm for the transaction. We are very excited for the possibilities of Vivakors line of nutraceutical products. Worldwide demand for nutraceutical products is expected to exceed $15 billion and Vivakor plans on being a substantial player in that market.

Dr. Fuja continued, We are particularly pleased to include in our new formulation the powerful, super-antioxidant star Yumberry (yang-mei in Chinese) also known as red bayberry thats harvested from one hundred-year-old trees and the flavonoid-rich concord grape shown to contain potent antioxidants that may protect against oxidative stress and reduce the risk of free radical damage and chronic diseases.

Regenecas President, Larry Walter gave his thoughts on the purchase.

From our standpoint, this transaction makes a great deal of sense. The pilot program we completed with Vivakor demonstrated great promise for the product from both a commercial and personal health perspective. Regeneca is certain to be able to develop a strong niche in the nutraceutical market with this terrific product.

Monday Nov. 9, 2009 Vivakor Announces Completion of Pilot Production Evaluation of Nutraceutical Product with Consumer Product Specialist, Regeneca International, Inc.

Vivakor Inc., announced it has completed a pilot product evaluation program with consumer product specialist, Regeneca International, Inc.

( www.regeneca.com). The product evaluation involved Vivakors proprietary nutraceutical formulation derived from natural sources. Research has shown that phytochemicals, vitamins, minerals, and fiber, all present in fruits and vegetables, work synergistically to promote health and lower disease risk. For this reason, many organizations, such as the National Cancer Institute and The American Heart Association, recommend getting phytochemicals from whole foods, such as fruits and vegetables. The Vivakor product is a whole food supplement designed to deliver these essential nutrients to the users in small, single dose units.

Regenecas President, Larry Walter gave his thoughts on the study.

Not only are the consumer study results impressive, but the overall opportunity to work with the team of professionals at Vivakor gives us a great deal of optimism for our future dealings with the company.

The parties plan additional studies with the hope of a market ready product by early 2010.

Vivakor, Inc. is a transdisciplinary research company that develops products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds. The Company also provides contract research services for third parties. Vivakor has developed numerous products and have filed many patents or provisional patents with the United States Patent and Trademark Office (USPTO). They intend to commercialize such products, after completion of any required regulatory approvals, through one of three methods: a sale of the technology, licensing of the product to a manufacturer or distributor or, in some cases, by manufacturing, marketing and directly selling the products themselves.

Stay tuned for more News and Updates on VIVK this week!!! Regards, FHPS Staff _____________________________________________________________________________ The disclaimer is to be read and fully understood before using our site, or joining our email list.

See Free Hot Penny Stocks's website for full disclaimer. Free Hot Penny Stocks may have received compensation for stock picks.